An open-label, two-week pilot treated 12 people with narcolepsy using reboxetine. Sleepiness and cataplexy measures improved in this small uncontrolled study; it cannot substitute for a modern randomized AXS-12 trial.
Program relevance
An early reboxetine narcolepsy pilot predates the branded AXS-12 program and is not its modern phase 3 trial.
Formulation / population: Oral reboxetine; the paper does not establish the later branded AXS-12 formulation.
In orexin-deficient mice, reboxetine and escitalopram reduced narcoleptic episodes, with reboxetine active at lower doses in this model. This supports a mechanistic hypothesis about norepinephrine signaling, not human treatment efficacy.
Program relevance
Reboxetine was tested in a mouse narcolepsy model, not in a human AXS-12 study.
Formulation / population: Reboxetine administered in an orexin-deficient mouse model.
Mouse model; not human clinical efficacy evidence.